Genzyme Care Coordination

Personalized Support

Genzyme Case Managers provide free and confidential care coordination, support and services to individuals living with Gaucher disease and their health care providers who reside in the United States. Our Case Managers will work closely with you, your staff and your patient to help coordinate access to treatment with Cerezyme®.

By referring your patients to a Genzyme Case Manager, they will have access to comprehensive care coordination services that include:

Personalized Case Management

Your patient will be assigned their own Case Manager who will provide:

  • One-on-one support tailored to you and your patient’s needs
  • Information about treatment with Cerezyme and related insurance coverage
  • Educational materials about Gaucher disease
  • Access to other Genzyme resources, including field-based support for you and your staff

Reimbursement Support

Simplify the reimbursement process for you and your staff by helping to:

  • Navigate the reimbursement process for treatment with Cerezyme
  • Verify your patient’s insurance coverage for treatment
  • Obtain a prior authorization, if necessary
  • Assist with billing and claims issues, including appeals for denied claims

Your Call, Our Commitment

A Genzyme Case Manager is only a phone call away from providing personalized assistance to you, your staff and your patients.

1-800-745-4447, Option 3
Monday through Friday, 8:00 AM to 6:00 PM EST

Information you or your patients provide will always be kept confidential. Genzyme offers all Care Coordination services in compliance with patient privacy regulations (HIPAA).

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  1. anemia
  2. thrombocytopenia
  3. bone disease
  4. hepatomegaly or splenomegaly

Important Safety Information

Approximately 15% of patients have developed IgG antibodies to Cerezyme during the first year of therapy. Approximately 46% of patients with detectable IgG antibodies experienced symptoms of hypersensitivity, and these patients have a higher risk of hypersensitivity. It is suggested that patients be monitored periodically for IgG antibody formation during the first year of treatment.

Hypersensitivity has also been observed in patients without detectable IgG antibodies. Symptoms suggestive of hypersensitivity have been noted in approximately 6.6% of all patients, and anaphylactoid reactions in less than 1%. Treatment with Cerezyme should be approached with caution in patients who have exhibited hypersensitivity symptoms such as pruritus, flushing, urticarial, angioedema, chest discomfort, dyspnea, coughing, cyanosis, and hypotension. Pre-treatment with antihistamines and/or corticosteroids and a reduced rate of infusion may allow continued treatment in most patients.

In less than 1% of patients, pulmonary hypertension and pneumonia have been observed during treatment with Cerezyme. These are known complications of Gaucher disease regardless of treatment. Patients with respiratory symptoms in the absence of fever should be evaluated for the presence of pulmonary hypertension.

Approximately 13.8% of patients have experienced adverse events related to treatment with Cerezyme. Some of these are injection site reactions such as discomfort, pruritus, burning, swelling or sterile abscess at the site at the site of venipuncture. Additional adverse reactions that have been reported include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Transient peripheral edema has also been reported for this therapeutic class of drug.

To report suspected adverse reactions, contact Genzyme at 800-745-4447, option 2 or FDA at 800-FDA-1088 or http://www.fda.gov/Safety/MedWatch

Please see Full Prescribing Information (PDF).